1 Brand-New Big Reason to Buy This Biotech Stock Right Now

With its shares skyrocketing by upwards of 74% on Oct. 16, Wave Life Sciences (NASDAQ: WVE) is now on the map of many investors. Per an update from one of its early-stage clinical trials, it just marked a first-in-humans scientific milestone. That cleared the way for its stock to continue gaining value as the biotech builds on its preliminary results.So what exactly did this company accomplish, and how important is it going to be in the long run for investors who buy it today? Let's get down to the details.Wave's mandate is to develop genetic medicines to treat rare inherited diseases like alpha-1 antitrypsin deficiency (AATD) and Duchenne muscular dystrophy (DMD). Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool